MGO One Seven’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $220K | Buy |
1,278
+32
| +3% | +$5.93K | ﹤0.01% | 1296 |
|
|
2025
Q4 | $249K | Sell |
1,246
-66
| -5% | -$12K | 0.01% | 1202 |
|
|
2025
Q3 | $205K | Buy |
+1,312
| New | +$208K | ﹤0.01% | 1242 |
|
|
2024
Q4 | – | Sell |
-1,332
| Closed | -$262K | – | 1078 |
|
|
2024
Q3 | $262K | Sell |
1,332
-182
| -12% | -$37.8K | 0.01% | 824 |
|
|
2024
Q2 | $313K | Sell |
1,514
-22
| -1% | -$4.99K | 0.01% | 754 |
|
|
2024
Q1 | $416K | Sell |
1,536
-403
| -21% | -$96.2K | 0.02% | 594 |
|
|
2023
Q4 | $458K | Sell |
1,939
-229
| -11% | -$45K | 0.03% | 562 |
|
|
2023
Q3 | $425K | Sell |
2,168
-47
| -2% | -$9.65K | 0.03% | 497 |
|
|
2023
Q2 | $466K | Buy |
2,215
+78
| +4% | +$15.5K | 0.04% | 433 |
|
|
2023
Q1 | $431K | Sell |
2,137
-10
| -0.5% | -$2.27K | 0.03% | 528 |
|
|
2022
Q4 | $468K | Sell |
2,147
-202
| -9% | -$44.1K | 0.05% | 417 |
|
|
2022
Q3 | $648 | Sell |
2,349
-116
| -5% | -$25K | 0.03% | 330 |
|
|
2022
Q2 | $527K | Sell |
2,465
-360
| -13% | -$88K | 0.07% | 303 |
|
|
2022
Q1 | $802K | Sell |
2,825
-737
| -21% | -$227K | 0.09% | 254 |
|
|
2021
Q4 | $1.34M | Buy |
3,562
+119
| +3% | +$46.2K | 0.14% | 170 |
|
|
2021
Q3 | $1.54M | Sell |
3,443
-217
| -6% | -$90.1K | 0.2% | 136 |
|
|
2021
Q2 | $1.35M | Buy |
3,660
+88
| +2% | +$29.4K | 0.19% | 143 |
|
|
2021
Q1 | $1.03M | Sell |
3,572
-29
| -0.8% | -$8.06K | 0.18% | 143 |
|
|
2020
Q4 | $900K | Sell |
3,601
-178
| -5% | -$42.4K | 0.19% | 139 |
|
|
2020
Q3 | $856K | Sell |
3,779
-89
| -2% | -$18.5K | 0.2% | 124 |
|
|
2020
Q2 | $674K | Sell |
3,868
-212
| -5% | -$33.8K | 0.18% | 156 |
|
|
2020
Q1 | $514K | Sell |
4,080
-214
| -5% | -$32.1K | 0.17% | 165 |
|
|
2019
Q4 | $655K | Sell |
4,294
-31
| -0.7% | -$4.29K | 0.17% | 162 |
|
|
2019
Q3 | $573K | Buy |
4,325
+130
| +3% | +$17.4K | 0.16% | 168 |
|
|
2019
Q2 | $595K | Sell |
4,195
-406
| -9% | -$55.1K | 0.19% | 156 |
|
|
2019
Q1 | $668K | Buy |
4,601
+2,106
| +84% | +$277K | 0.22% | 135 |
|
|
2018
Q4 | $282K | Sell |
2,495
-267
| -10% | -$33.4K | 0.12% | 189 |
|
|
2018
Q3 | $371K | Buy |
+2,762
| New | +$341K | 0.17% | 167 |
|
|
2018
Q1 | $312K | Sell |
2,923
-132
| -4% | -$14.2K | 0.14% | 171 |
|
|
2017
Q4 | $334K | Buy |
+3,055
| New | +$332K | 0.15% | 157 |
|
Other funds holding CRL
VCM
VPM
MGO One Seven's CRL Position: Q1 2026 in Review
MGO One Seven increased its Charles River Laboratories (CRL) stake by 2.6% in Q1 2026, buying an estimated $5.93K and bringing the position to 1,278 shares worth $220K. The position accounts for ﹤0.01% of the portfolio, ranked #1296.
MGO One Seven first reported a position in CRL in Q4 2017 and has held it in 30 quarters since. The position peaked at $1.54M in Q3 2021. 557 funds tracked by Wall St. Rank hold CRL as of Q1 2026.
- MGO One Seven held 1,278 shares of Charles River Laboratories worth $220K as of Q1 2026.
- MGO One Seven bought 32 Charles River Laboratories shares in Q1 2026, an estimated $5.93K.
- Charles River Laboratories made up ﹤0.01% of MGO One Seven's portfolio in Q1 2026, its #1296 holding.
- MGO One Seven first reported a position in Charles River Laboratories in Q4 2017 and has held it in 30 quarters since.
- MGO One Seven's Charles River Laboratories position peaked at $1.54M in Q3 2021.
- 557 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.
Based on MGO One Seven's 13F filing for Q1 2026, filed 14 May 2026.